Remtolumab

View Clinical trials for Remtolumab Get Remtolumab Patent Info for Free

ABT-122 works in a similar fashion as AbbVie's blockbuster Humira but with an added target. While Humira blocks TNF-alpha, ABT-122 blocks both TNF-alpha as well as IL-17.

Inn NameRemtolumab
Lab CodesA-1230717, ABT-122
Chemical NameImmunoglobulin G1-kappa, anti-[Homo sapiens IL17A (interleukin 17A, IL-17A) and Homo sapiens TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA)], Homo sapiens monoclonal antibody, tetravalent bispecific; gamma1 heavy chain (1-587) [Homo sapiens VH anti-TNF (IGHV3-9*01 (93.90%) -(IGHD) -IGHJ4*01) [8.8.14] (1-121) -10-mer bis(tetraglycyl-seryl) linker (122-132) -Homo sapiens VH’ anti-IL17A (IGHV1-69*01 (85.70%) -(IGHD) -IGHJ6*01) [8.8.19] (132-257) -IGHG1*01, G1m17,1 (CH1 (258-355), hinge (356-370), CH2 (371-480), CH3 (481- 585), CHS (586-587)) (258-587)], (360-331')-disulfide with kappa light chain (1'-331') [Homo sapiens V-KAPPA anti-TNF (IGKV1-27*01 (95.80%) -IGKJ2*01) [6.3.9] (1'-107') -
Homo sapiens V-KAPPA anti-IL17A (IGKV6-21*01 (90.50%) -IGKJ3*01) [6.3.9] (118'-224') -IGKC*01, Km3 (225'-213')]; dimer (366-366'':369-369'')-bisdisulfide
SequenceHeavy chain
EVQLVESGGG LVQPGRSLRL SCAASGFTFD DYAMHWVRQA PGKGLEWVSA 50
ITWNSGHIDY ADSVEGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAKVS 100
YLSTASSLDY WGQGTLVTVS SGGGGSGGGG SEVQLVQSGA EVKKPGSSVK 150
VSCKASGGSF GGYGIGWVRQ APGQGLEWMG GITPFFGFAD YAQKFQGRVT 200
ITADESTTTA YMELSGLTSD DTAVYYCARD PNEFWNGYYS THDFDSWGQG 250
TTVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS 300
GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK 350
VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT 400
CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH 450
QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK 500
NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL 550
TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK 587

Light chain
DIQMTQSPSS LSASVGDRVT ITCRASQGIR NYLAWYQQKP GKAPKLLIYA 50
ASTLQSGVPS RFSGSGSGTD FTLTISSLQP EDVATYYCQR YNRAPYTFGQ 100
GTKVEIKRGG SGGGGSGEIV LTQSPDFQSV TPKEKVTITC RASQDIGSEL 150
HWYQQKPDQP PKLLIKYASH STSGVPSRFS GSGSGTDFTL TINGLEAEDA 200
GTYYCHQTDS LPYTFGPGTK VDIKRTVAAP SVFIFPPSDE QLKSGTASVV 250
CLLNNFYPRE AKVQWKVDNA LQSGNSQESV TEQDSKDSTY SLSSTLTLSK 300
ADYEKHKVYA CEVTHQGLSS PVTKSFNRGE C 331

Disulfide bridges location
Intra-H (C23-C104) 22-96 153-227 284-340 401-461 507-565
22''-96'' 153''-227'' 284''-340'' 401''-461'' 507''-565''
Intra-L (C23-C104) 23'-88' 140'-205' 251'-311'
23'''-88''' 140'''-205''' 251'''-311'''
Inter-H-L (h 5-CL 126) 360-331' 360''-331'''
Inter-H-H (h 11, h 14) 366-366'' 369-369''

N-glycosylation sites
H CH2 N84.4:
437, 437''
Fucosylated complex bi-antennary CHO-type glycans
Chemical StructureRemtolumab.png
Cas Registry Number1791410-27-9
New Molecular EntityYes
OriginatorAbbott Laboratories
DeveloperAbbVie
Mechanism Of ActionTumor necrosis factor (TNF) alpha inhibitor; Interleukin-17 (IL-17) antagonist
Who Atc CodesM01 (Antiinflammatory and Antirheumatic Products)
Ephmra CodesM1 (Anti-Inflammatory and Anti-Rheumatic Products)
IndicationRheumatoid arthritis, Psoriatic arthritis

Free counters!